MACC1 and pancreatic neoplasm: This important finding was also confirmed in other cancer entities, with MACC1-high expressing gastric cancer (GC) cells demonstrating a poor response to oxaliplatin, whereas ovarian and lung cancer cell lines exhibited a poor response to cisplatin, and pancreatic cancer cells poorly responded towards gemcitabine treatment [42–45].